Liquid biopsies come of age: towards implementation of circulating tumour DNA. - Wikidata - wikimedia - TriplyDB

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

http://www.wikidata.org/entity/Q39149201

about

CVE: an R package for interactive variant prioritisation in precision oncology.The future of oncology therapeutics.Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma.Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.Personalized medicine could transform healthcare.Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors.Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.Breast cancer: The translation of big genomic data to cancer precision medicine.Cholangiocarcinoma - evolving concepts and therapeutic strategies.The bridge between transplantation and regenerative medicine: Beginning a new Banff classification of tissue engineering pathology.A conduit to metastasis: circulating tumor cell biology.Recent progress in nucleic acids isotachophoresis.Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer.Next generation sequencing: clinical applications in solid tumours.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA.Whole-body PET/MRI of Pediatric Patients: The Details That Matter.DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA.Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.Molecular roles and function of circular RNAs in eukaryotic cells.Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling.Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Urine test for EGFR analysis in patients with non-small cell lung cancer.Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.The clinical characteristics and prognostic analysis of Chinese advanced NSCLC patients based on circulating tumor DNA sequencing.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Liquid biopsy and its role in an advanced clinical trial for lung cancer.A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Patient monitoring through liquid biopsies using circulating tumor DNA.Can circulating tumor DNA be used for direct and early stage cancer detection?Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.

P2860

Q33730180-B7AA9F56-17CA-403B-B672-C9CD0D2FD5D3 Q38683944-3D12ED55-FB4E-4CFE-8CE1-3399C9B70D4F Q38716377-068B4BED-07C4-45B4-8F4D-B3F3DD137FA0 Q39304648-00706B4E-9206-4352-9277-3A668AF62B50 Q40169633-5496FE26-D9D6-4583-91D0-95E66653F035 Q40991086-3442BFC0-1A63-42BF-973A-A23F6E832F2C Q41524917-B0488B8C-360F-4C83-A184-2D0CFDCC0DF4 Q41605016-D04C7138-B2C4-4DB9-9D17-846A16E33593 Q42059581-96B313A7-C0EC-475D-9104-B7697E6E0CA2 Q42360040-E0472A79-EFDD-405B-B2D4-D32D90A4D114 Q42925962-453912ED-D959-42F8-84F0-84B63643AA69 Q45901388-FA25A58F-9B6F-4FC3-9428-7FB383595CD5 Q45943221-721D7C53-57A9-4932-8D86-58CCB07ACC40 Q46087686-599FE012-3E54-41B7-9C28-238620E13163 Q46112070-09388582-833B-472E-8FC7-91C5770412B1 Q46280012-0AE0BBDC-6E36-41D0-9208-D7887DFEBF22 Q46294352-D760A5B3-46A2-4290-B1CF-FF1F2EDDCDF7 Q47099537-080EED2A-1BB2-42E8-BBF1-2BA7F2F1C96B Q47121916-4ADD73DE-6DD4-434B-9721-84CD6887B596 Q47138927-6D023362-7610-49A2-A442-49D254F02D45 Q47153925-89D44466-425B-4EA4-ABB1-B52A2F1E5B58 Q47166342-3ABE2D24-443C-480B-BE39-B6C4BDF7D716 Q47167930-BF22651C-56F8-4C30-A3A5-6C95CF8CCAD0 Q47216527-AA0B435C-B547-49E0-8090-818CC43AD642 Q47299130-60FDEB4F-100A-49FB-831E-A70FA35AF782 Q47392574-88FECE24-0C26-460C-9BFF-36A616FEC03B Q47425702-C2E9731B-27B5-4508-BBAA-8725818F7CB1 Q47558605-48912E1D-BA31-4291-9901-88172ABF340E Q47562193-897831E5-514C-49F2-87CC-9585EF575211 Q47563363-C20B0E12-A61A-4FE2-A96D-E07B4797AE5B Q47564108-DB2B5237-868D-4F95-B4D2-7B2BD145FDF0 Q47569690-790B2685-9E7C-42E3-8917-940C10D2A5D1 Q47608030-EFDE699F-16AC-4D19-A4B4-2A693B3E6A44 Q47825070-5BFF973E-C6C5-4743-9F97-388C9DFC5150 Q47936526-4EF2E229-DF17-48E7-927F-5F354A9C0C19 Q48098593-C14063B5-CA78-4678-A4DE-0A6D51A717CD Q48178985-B4D1A411-35AB-4D96-A2F7-7E04F5CD2655 Q48194423-A26A9B76-9396-4E91-AD91-DE691FC53563 Q48247046-226D6180-BDCA-4A74-A76C-0C8B6B0A74A1 Q48277300-1A45BB10-4796-4BEC-9090-13D58B71DBA5

P2860

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

http://www.wikidata.org/entity/Q39149201

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@en

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@nl

type

label

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@en

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@nl

prefLabel

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@en

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@nl

P1433

Q39149201-B3F689CB-119B-4939-B060-A84AC5AFEFDD

P1476

Q39149201-43F1FB3F-6C3E-48EB-B10D-003A461BBCF4

P2093

Q39149201-44926BB7-E488-49B3-86D3-4A9E05CA93E4

Q39149201-735A740E-A818-4EA6-AE03-A64BF98F9484

Q39149201-7FE5C17E-DA3B-4DC5-9550-242762974544

Q39149201-8C2E62B8-4212-42E5-9145-337CAE98D3EE

Q39149201-B8148235-1694-4A51-A6D9-20C858974019

Q39149201-FF8BA82D-515C-478E-8BBE-020939502B97

P2860

Q39149201-017E01D2-5F39-4403-A781-E498221B646C

Q39149201-01DD399F-80D6-4458-BC5A-0102628FED7F

Q39149201-025C543E-373D-4A1B-979F-3B5388E78BB2

Q39149201-027740E5-53F8-417E-BBD0-4147549B3F4A

Q39149201-06830339-0BAD-427A-824F-74ADEF6FB6F7

Q39149201-0A5EB456-B11A-4AAD-AD31-B11353D30341

Q39149201-0B8CDC8D-BAFE-4CA3-80E5-7135FC6ECBD3

Q39149201-0CB16DF1-75A6-4118-A599-CEE1C1996EBD

Q39149201-0DA61E28-241A-442E-A0BE-4035185CA3E1

Q39149201-0F487CE5-F2BC-4338-9C4F-F1922BADBEF2

P2888

Q39149201-4F361A1F-6D5D-4778-A945-9C35357D04DC

P304

Q39149201-DE4093A8-A581-4444-9859-7B2FBE5A7C32

P31

Q39149201-F8F9720D-4B6D-4343-8A1A-767DCA147AA2

P356

Q39149201-5F54FA61-B808-4D79-8D29-412A7A8486F5

P407

Q39149201-C8089251-9144-426D-AE4E-D183BBA83F30

P433

Q39149201-1F434139-2A06-4EE4-B75D-D2A3E439382E

P478

Q39149201-A871F56E-607B-486E-B7AF-AB880ED50ACA

P50

Q39149201-38D0D0B5-7B56-4E45-AFED-240F10775293

Q39149201-6D30BE3D-D84C-4C64-B93E-65A2A70E9EC4

Q39149201-E005B420-F3BB-44C7-94D8-712A76ABFDEB

P577

Q39149201-8F199AEA-74CE-4CE3-BAE1-BFC480120F66

P698

Q39149201-595E7666-A832-4D05-AEAC-E835F63EA9B0

P921

Q39149201-AE45F710-C421-4519-AA95-C0C5FB0A2857

P356

P1433

Nature Reviews Cancer

P1476

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

@en

P2093

Carlos Caldas

http://www.w3.org/2001/XMLSchema#string

Charles Massie

http://www.w3.org/2001/XMLSchema#string

James D Brenton

http://www.w3.org/2001/XMLSchema#string

Javier Garcia-Corbacho

http://www.w3.org/2001/XMLSchema#string

Nitzan Rosenfeld

http://www.w3.org/2001/XMLSchema#string

Simon Pacey

http://www.w3.org/2001/XMLSchema#string

P2860

Real-time, portable genome sequencing for Ebola surveillance

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

Non-invasive prenatal testing: a review of international implementation and challenges

Fragment Length of Circulating Tumor DNA

Long-term dual-color tracking of genomic loci by modified sgRNAs of the CRISPR/Cas9 system.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Double-stranded DNA in exosomes: a novel biomarker in cancer detection

P2888

P304

223-238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRC.2017.7

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Florent Mouliere

Jonathan C M Wan

P577

2017-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28233803

http://www.w3.org/2001/XMLSchema#string

P921